Events

Field Safety Notices about nexgen precoat/option stem with tibia

According to Danish Medicines Agency, this field safety notices involved a device in Denmark that was produced by Zimmer, Inc..

What is this?

Field safety notices are communications sent out by medical device manufacturers or their representatives in relation to actions that they may be taking in relation to their product that is on the market. These are mainly for health workers, but also for users. They can include recalls and alerts.

Learn more about the data here
  • Type of Event
    Field Safety Notice
  • Event Number
    2016013365
  • Date
    2016-01-25
  • Event Country
    Denmark
  • Event Source
    DMA
  • Event Source URL
    https://laegemiddelstyrelsen.dk/da/udstyr/sikkerhedsmeddelelser/2016/01/nexgen-precoatoption-stemmed-tibia/
  • Notes / Alerts
    Danish data is current through March 2019. All of the data comes from the Danish Medicines Agency, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Denmark.
  • Extra notes in the data

Device

nexgen precoat/option stem with tibia

Manufacturer

Zimmer, Inc.
  • Manufacturer Parent Company (2017)
    Zimmer Biomet Holdings
  • Manufacturer comment
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    DMA